Results 101 to 110 of about 11,695 (199)

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2232-2245, November 2026.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Increased gene expression of CCR6 and RORγt in peripheral blood cells of rheumatoid arthritis patients and their correlation with anti-cyclic citrullinated peptide and disease activity. [PDF]

open access: yesImmun Inflamm Dis, 2023
Roghani SA   +9 more
europepmc   +1 more source

Unexplained Optic Neuritis and New Heart Block: A Diagnostically Challenging Case of Probable Sarcoidosis

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Sarcoidosis is a systemic inflammatory disease of unknown etiology and manifests in multiple forms. It can affect several organs within the body; however, the lungs and intra‐thoracic lymph nodes are involved in the majority of cases. Diagnosis can be challenging due to the diversity of presentation and similarities to other systemic diseases.
Chetan Kamath   +4 more
wiley   +1 more source

A Case of Recurrent Gastric Cancer in Which Rheumatoid Arthritis and Sjögren's Syndrome Became Evident With Nivolumab

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT A 59‐year‐old man with recurrent gastric cancer began nivolumab as third‐line therapy and subsequently experienced joint pain and dry eyes. Symptoms worsened despite NSAIDs. He was diagnosed with rheumatoid arthritis and Sjögren's syndrome, associated with nivolumab, and was successfully treated with immunosuppressive and anti‐rheumatic ...
Haruhiko Takemoto   +7 more
wiley   +1 more source

Diagnostic Pitfall: Mixed Connective Tissue Disease‐Associated Pulmonary Hypertension Presenting With Postpartum Right‐Sided Heart Failure in a 21‐Year‐Old—Case Report

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Mixed connective tissue disease is a multisystem autoimmune condition characterized by overlapping clinical and serological features related to anti‐U1‐RNP antibodies of at least two connective tissue diseases. It may present with myocarditis, pericarditis, pulmonary arterial hypertension, and, less commonly, heart failure.
Sai Santhosha Mrudula Alla   +10 more
wiley   +1 more source

C3a‐C3aR Signaling Modulates Neutrophil Extracellular Traps Formation and Contributes to Blood–Brain Barrier Injury After Stroke

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 11, November 2026.
Following ischemic stroke, C3a‐C3aR signaling was associated with increased neutrophil extracellular traps (NETs) formation, blood–brain barrier (BBB) disruption, and neurological impairment. Pharmacological modulation of C3a‐C3aR signaling or NETs formation attenuated BBB injury and improved neurological outcomes, supporting a potential role of C3a ...
Qingtong Zhang   +7 more
wiley   +1 more source

Anti-Cyclic Citrullinated Peptide Antibody Index in the Cerebrospinal Fluid for the Diagnosis and Monitoring of Rheumatoid Meningitis. [PDF]

open access: yesBiomedicines, 2022
Caputi L   +9 more
europepmc   +1 more source

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy